Nuwellis Inc vs Target Corporation — how do they compare? Nuwellis Inc trades at $0.69 (market cap $2.20M), while Target Corporation trades at $153.77 (market cap $70.31B). The key difference: Target Corporation is far larger — about 31959.1× Nuwellis Inc's market cap, and Target Corporation pays a 3% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Target Corporation for 137 Days on average.
| NUWE | TGT | |
|---|---|---|
Market Cap | $2.20M | $70.31B |
Volume | 121,544 | 4,164,999 |
Sector | Health | Consumer Staples |
52-Week High | $146.65 | $169.90 |
52-Week Low | $0.68 | $83.68 |
Typical Hold Time | 26 Days | 137 Days |
Enterprise Value | -$1.52M | $83.58B |
Dividend Yield | — | 3% |
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.689, down 0.25% with a bearish technical signal despite oversold RSI readings. The company shows promising revenue growth (14% YoY in Q2 2026) and strong gross margins (69.69%), but faces significant profitability challenges with a -125.63% net income margin and negative cash flow. Recent news highlights console adoption growth and strategic expansions in pediatric care.
While NUWE's valuation metrics appear attractive (P/E 0.03, P/S 0.01), the company's persistent losses and negative cash flow present substantial risk. Analyst sentiment is mixed with a 50/50 buy/hold split. The stock offers speculative potential if management can achieve profitability, but requires careful risk assessment given current financial challenges.
Target Corporation (TGT) trades at $154.76, up 2.52% with strong recent earnings beats. The stock shows bearish technical signals but maintains solid fundamentals with a 26.41% ROE and 4.08% net margin. Recent price cuts on 2,000 items aim to capture holiday market share, while analyst consensus targets $167.18 with 47% buy ratings. Cash flow remains positive at $957M despite competitive retail pressures.
Target presents a mixed outlook with valuation appeal (P/E 16.05) against bearish technicals. Upside potential exists from continued earnings outperformance and dividend stability, but risks include margin pressure from price investments and weak consumer spending. The stock offers value for patient investors despite near-term volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →